Christopher Haqq

Insider Reports History

Location
C/O Atara Biotherapeutics, Inc., 3260 Bayshore Boulevard, Brisbane, CA
Signature
/s/ Christopher Haqq
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Haqq:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Surrozen, Inc./DE Former Director Common Stock 30K $11.4K $0.38 Aug 11, 2021 Direct
Elicio Therapeutics, Inc. Executive Vice President, Head of R&D and Chief Medical Officer Stock Option (Right to Buy) 44K Feb 3, 2025 Direct
Surrozen, Inc./DE Former Director Class B Ordinary Shares 0 Aug 11, 2021 Direct

Insider Reports Filed by Christopher Haqq

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ELTX Elicio Therapeutics, Inc. Feb 3, 2025 1 $0 4 Feb 4, 2025 Executive Vice President, Head of R&D and Chief Medical Officer
ELTX Elicio Therapeutics, Inc. Sep 30, 2024 1 $0 4 Oct 2, 2024 Title: Executive Vice President, Head of R&D and Chief Medical Officer
ELTX Elicio Therapeutics, Inc. Feb 1, 2024 1 $0 4 Feb 5, 2024 Title: Executive Vice President, Head of R&D and Chief Medical Officer
ELTX Elicio Therapeutics, Inc. Jun 1, 2023 0 $0 3 Jun 12, 2023 Exhibit 24.1 - Power of Attorney. Title: Executive Vice President, Head of R&D and Chief Medical Officer
SRZN Surrozen, Inc./DE Aug 11, 2021 2 $0 4 Aug 13, 2021 Former Director